Advicenne S.A. (EPA:ALDVI)
France · Delayed Price · Currency is EUR 1.330
-0.040 (-2.92%)
Sep 16, 2025, 5:35 PM CET
Advicenne Company Description
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally.
The company offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria.
It also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures.
Advicenne S.A. was incorporated in 2007 and is headquartered in Paris, France.
Advicenne S.A.
| Country | France |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Didier Laurens |
Contact Details
Address: 3Eme Etage Paris, 75008 France | |
| Phone | 33 1 85 73 36 20 |
| Website | advicenne.com |
Stock Details
| Ticker Symbol | ALDVI |
| Exchange | Euronext Paris |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR0013296746 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Laurent Cassedanne | Deputy Chief Executive Officer, Deputy GM and Head Pharmacist and Director |
| Didier Laurens | Chief Executive Officer, MD, General Director and Director |
| Isabelle Kervella | Chief Financial Officer |
| Dr. André Ulmann M.D., Ph.D. | Chief Medical Officer and Non-Voting Director |
| Hege Hellstrom | Chief Commercial Officer |
| Robbie McCarthy | General Manager of Advicenne Inc. |